CytomX Therapeutics (NASDAQ: CTMX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare CytomX Therapeutics to related businesses based on the strength of its risk, valuation, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Volatility and Risk
CytomX Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, CytomX Therapeutics’ peers have a beta of 6.15, indicating that their average stock price is 515% more volatile than the S&P 500.
This table compares CytomX Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|CytomX Therapeutics||$15.04 million||-$58.90 million||-13.89|
|CytomX Therapeutics Competitors||$284.49 million||$33.78 million||82.67|
CytomX Therapeutics’ peers have higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
63.2% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.7% of CytomX Therapeutics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations for CytomX Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|CytomX Therapeutics Competitors||867||3223||11703||232||2.71|
CytomX Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 49.46%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.04%. Given CytomX Therapeutics’ higher probable upside, equities analysts plainly believe CytomX Therapeutics is more favorable than its peers.
This table compares CytomX Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CytomX Therapeutics Competitors||-5,302.25%||-218.50%||-39.57%|
CytomX Therapeutics peers beat CytomX Therapeutics on 7 of the 12 factors compared.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.